LOS ANGELES, March 12, 2018 /PRNewswire/ -- CytRx
Corporation (NASDAQ: CYTR), a biopharmaceutical research and
development company specializing in oncology, today announced that
it will report financial results for the full year ended
December 31, 2017 on Monday, March 19, 2018. CytRx's executives
Steven Kriegsman, Chairman and CEO,
and John Caloz, Chief Financial
Officer, will hold a conference call and webcast beginning at
11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on that day to discuss
the results.
To access the conference call, dial 844-358-6753 (U.S. and
Canada) or 216-562-0397
(international callers) and enter the conference ID number:
8178698. A live and archived webcast will be available in the
investor relations section of the company's website,
www.cytrx.com. A replay of the call and webcast will begin
approximately two hours after the live call has ended. To
access the replay, dial 855-859-2056 (U.S. and Canada) or 404-537-3406 (international
callers) and enter the conference ID number: 8178698.
About CytRx Corporation
CytRx Corporation is a biopharmaceutical company specializing in
research and clinical development of novel anti-cancer drug
candidates that employ linker technologies to enhance the
accumulation and release of drug at the tumor. CytRx is also
rapidly expanding its pipeline of ultra-high potency oncology
candidates at its laboratory facilities in Freiburg, Germany, through its LADR™ (Linker Activated
Drug Release) technology platform, a discovery engine designed to
leverage CytRx's expertise in albumin biology and linker technology
for the development of a new class of potential breakthrough
anti-cancer therapies. Aldoxorubicin, CytRx's most advanced
drug conjugate, is an improved version of the widely used
anti-cancer drug doxorubicin and has been out-licensed to NantCell,
Inc.
Forward-Looking Statements
This press release contains forward-looking statements. Such
statements involve risks and uncertainties that could cause actual
events or results to differ materially from the events or results
described in the forward-looking statements, including risks and
uncertainties relating to the ability of NantCell, Inc., to obtain
regulatory approval for its products that use aldoxorubicin; the
ability of NantCell, Inc., to manufacture and commercialize
products or therapies that use aldoxorubicin; the amount, if any,
of future milestone and royalty payments that we may receive from
NantCell, Inc.; our ability to develop new ultra-high potency drug
candidates based on our LADRTM technology platform; and
other risks and uncertainties described in the most recent annual
and quarterly reports filed by CytRx with the Securities and
Exchange Commission and current reports filed since the date of
CytRx's most recent annual report. All forward-looking statements
are based upon information available to CytRx on the date the
statements are first published. CytRx undertakes no obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.
Investor Relations Contact:
Argot Partners
Michelle Carroll/Sean Augustine-Obi
(212) 600-1902
michelle@argotpartners.com
sean@argotpartners.com
View original
content:http://www.prnewswire.com/news-releases/cytrx-to-hold-year-end-2017-financial-results-conference-call-and-webcast-on-monday-march-19-2018-300612142.html
SOURCE CytRx Corporation